We have recently developed a non-cytopathic RNA repliconbased viral vector system based on the flavivirus Kunjin. Here, we illustrate the utility of the Kunjin replicon system for gene therapy. Intra-tumoral injections of Kunjin replicon virus-like particles encoding granulocyte colony-stimulating factor were able to cure 450% of established subcutaneous CT26 colon carcinoma and B16-OVA melanomas. Regression of CT26 tumours correlated with the induction of anticancer CD8 T cells, and treatment of subcutaneous CT26 tumours also resulted in the regression of CT26 lung metastases. Only a few immune-based strategies are able to cure these aggressive tumours once they are of a reasonable size, illustrating the potential of this vector system for intra-tumoral gene therapy applications.
Introduction
Intra-tumoral gene therapy (the transfection of tumour cells in situ) is emerging as a viable strategy for treating malignant disease in humans. Several virally vectored gene therapies have shown significant clinical activity in human trials 1, 2 and one, gendicine, has been licensed. 3 A major limiting factor in the development of such therapies is the paucity of delivery modalities that safely provide sustained high-level gene expression in vivo. 4 We have recently developed a novel, non-cytopathic, RNA replicon-based gene delivery system based on the Australian flavivirus Kunjin (KUN). 5 A number of replicon-based systems have been developed, 6 with alphavirus-based replicons perhaps the best studied. 7 The basic principle underpinning most RNA replicon systems is the replacement of the structural genes in the viral genome with a heterologous gene. The replicon RNA can be packaged into virus-like particles (VLPs) by supplying the structural proteins in trans in packaging cell lines. 8 The resulting VLPs can then be used to infect/ transfect cells where the replicon RNA is then massively and continually amplified by replicon-encoded RNA replicases. The high levels of RNA ensure high levels of heterologous gene expression, and the double-stranded RNA (dsRNA) replication intermediates induce interferon (IFN)-a/b and other 'danger signals'. 5 As no structural genes are encoded in the replicon genome, no production of infectious virus particles occurs and infection is limited to a single round. In addition, VLPbased replicon vectors deliver only RNA, thereby avoiding any potential complications associated with DNA chromosome integration. The additional features associated with KUN replicons are (i) they were derived from Kunjin virus, which is endemic in Northern Australia and usually causes asymptomatic infection in humans, with very rare cases of mild fever and/or mild encephalitis; 9 (ii) the majority of the world's populations do not have neutralizing antibodies directed at KUN virus; (iii) the RNA polymerase enzymes of flaviviruses appear to replicate RNA with high fidelity, 10 an observation confirmed by us for the KUN replicon system (unpublished data); (iv) RNA recombination in flavivirus systems appears to be extremely rare, and thus the risk of generating potentially infectious recombinant viruses both in treated patients and during VLP generation is very low and (v) KUN replicons do not induce overt apoptosis or cytopathic effects. 5 RNA recombination occurs frequently in alphavirus systems, and this can lead to the generation of replication-competent recombinant viruses. 11 In addition, in conventional alphavirus systems, replicon transfection results in the induction of apoptosis/cytopathic effects, and thus protein production is terminated within a few days. In contrast, KUN replicon transfection does not result in cytopathic effects, resulting in sustained therapeutic protein production. Furthermore, when KUN replicon-transfected cells divide, both daughter cells retain replicon RNA and continue to produce recombinant protein. 12 After the discovery that vaccines comprising irradiated autologous tumour cells expressing granulocyte macrophage colony-stimulating factor (GM-CSF) generate effective anti-cancer CD8 T cells, GM-CSF has been extensively studied for its utility against cancers, and the approach has now been used in a number of clinical trials. 13 More recently with the advent of intra-tumoral immunotherapy, 14 a number of approaches have been developed that result in GM-CSF secretion in the tumour environment in situ, thereby avoiding the requirement to manipulate autologous tumour cells in vitro. Intratumoral GM-CSF delivery modalities include DNA, 15, 16 vaccinia, 17 encapsulated microspheres, 18 bioadhesive hydrogels 19 and disabled infectious single cycle (DISC)-herpes simplex virus (HSV) vectors. 20 DISC/HSV-GM-CSF has completed phase I trials of melanoma with promising results. 2 Dendritic cell attraction and maturation appear to be the critical components of GM-CSF's mechanism of action, 21, 22 with tumour destruction largely dependent on anti-cancer CD8 T cells. 20, [23] [24] [25] IFN-a/b is approved for the treatment of several cancers and mediates a range of direct activities against cancers, the best known of which are slowing of the cell cycle, promotion of differentiation, anti-angiogenesis and promotion of apoptosis. 26 IFN-a/b is also an important link between the innate and adaptive immune systems. IFN-a/b promotes the generation of Th1-biased CD8 T cells through the stimulation of dendritic cells. 27, 28 IFN-atreated dendritic cells also have higher interleukin (IL)-12-producing ability and generate increased numbers of anti-cancer CD8 T cells. 29 IFN-a/b also acts directly on CD8 T cells to promote survival, clonal expansion, differentiation and memory. [30] [31] [32] [33] Transfection-mediated expression of IFN-a/b by tumour cells in vivo also enhances anti-cancer activity, 34 including anti-cancer CD8 T cells. 35 Furthermore, IFN-a/b has been shown to synergize with GM-CSF to improve CD8 T-cell induction by dendritic cells. 36, 37 Therapy with a GM-CSF-secreting tumour cell vaccine was also shown to be substantially enhanced when IFN-a was injected into the tumour site, with the improved therapy associated with increased anti-cancer CD8 T cells. 24 Herein we sought to exploit the synergy between IFN-a/ b and GM-CSF for intra-tumoral gene therapy by constructing a Kunjin replicon vector encoding GM-CSF. A mutation was also introduced into the vector's non-structural protein NS2A ( 30 Ala to 30 Pro), which was expected to increase the level of IFN-a/b production by replicon-transfected cells. We have shown earlier that this mutation disables the virus's ability to limit IFN-a/b induction without affecting heterologous gene expression.
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Results
The KUN GM-CSF construct
The KUN GM-CSF replicon construct is shown in Figure 1a . The various elements of KUN replicon constructs and their roles have been described earlier. 5 The GM-CSF gene is flanked by a foot and mouth disease virus 2A autoprotease site (FMDV2A) and an internal ribosome entry site (IRES) of encephalomyocarditis virus. These elements ensure that GM-CSF protein is detached from the C20 sequence at its N terminus and that the non-structural proteins (which encode the RNA replicases) are translated despite the stop codon at the end of the GM-CSF gene. In vitro-transcribed RNA was used to generate KUN GM-CSF VLPs by transfection of a packaging cell line, which supplies the KUN structural proteins in trans. 8 After infection of cells, the KUN replicon-encoded RNA replicases massively amplify the replicon RNA, resulting in a large number of RNA molecules encoding GM-CSF. The dsRNA replication intermediates also induce 'danger signals', which results in the secretion of IFN-a/b (Figure 1b) . 5 
Secretion of GM-CSF and IFN-a/b in vitro
A GM-CSF bioassay was used to illustrate that KUN GM-CSF VLP-infected, but not uninfected, cells produced GM-CSF. In these assays, B55-90% of Vero cells were infected with VLPs as determined by immunofluorescence antibody (IFA) staining (data not shown). The range of bioactive GM-CSF produced per cell every 60 h was thus 0.26-0.43 pg (Figure 2a) . Similar values were obtained when KUN GM-CSF VLPs were used to infect BHK and B16 cells (data not shown). This compares with 0.15 pg/cell every 24 h secreted by B16 cells stably transfected with a DNA plasmid encoding murine GM-CSF 40 and B0.2 pg/cell every 24 h for CHO cells stably expressing human GM-CSF. 41 For the DISC-human GM-CSF system, GM-CSF production was reported to be 0.023-0.3 pg/cell every 24 h for a range of human cancer cell lines. We have recently identified a mutation, 30 Ala to 30 Pro (A30P) in the non-structural protein NS2A of KUN, which disables the virus's ability to limit IFN-a/b induction. 38, 39 As expected, cells infected with VLPs containing this NS2A/A30P mutation produced substantially more IFN-a/b VLPs than wild-type (WT) VLPs at 18 h after infection (Figure 2b ). Assuming a bioactivity of 2.18 Â 10 8 U mg
À1
, KUN A30P VLP-infected cells produced about 6 ng IFN-a/b/10 6 cells every 18 h, which is comparable to the 7.8 ng IFN-a/10 6 cells every 18 h produced by tumour cells transfected with a DNA plasmid encoding IFN-a, 43 but at an order of magnitude less than that produced by tumour cells transfected with an adenovirus vector encoding IFN-a. 35 All experiments described herein used KUN GM-CSF VLPs containing the NS2A/A30P mutation.
Although one might predict that the increased IFN-a/b production from replicons with the NS2A/A30P mutation should inhibit replicon RNA replication (and therefore GM-CSF production), this is not the case because NS2A, NS2B, NS3, NS4A and NS4B also inhibit IFN-a/b receptor signalling. 44 Thus, although the replicon-transfected cells secrete IFN-a/b, they are resistant to the antiviral activity of IFN-a/b. Importantly, this resistance to the anti-viral effects of IFN-a/b is retained in cells transfected with replicons containing the NS2A/ A30P mutation (WJ Liu and AA Khromykh, unpublished observation).
Insert stability
We 45 and others 46 have noted that flavivirus VLPs can loose expression of certain inserted genes through mechanisms that are currently poorly understood. The potential for genetic instability is not unique to flavivirus replicons and has been described for many recombinant viral vectors. [47] [48] [49] [50] [51] We have observed that for unstable Kunjin replicons, insert deletion occurs during VLP generation in the packaging cell line, and extending the time between RNA transfection of the packaging cell line and harvesting of the VLPs increases the proportion of VLPs not expressing the inserted gene. 45 To examine the insert stability of the KUN GM-CSF VLPs, VLPs harvested at days 2, 3 and 4 were analyzed by IFA to determine the infectious titre of VLPs using anti-NS1 and anti-GM-CSF antibodies. An example of the IFA images obtained is shown in Figure 2c , which illustrate that after VLP infection (at multiplicity of infection (MOI) ¼ 0.04), nearly all the cells expressing NS1 also express GM-CSF. This was repeated for VLPs harvested at days 3 and 4, and the data derived from anti-NS1 and anti-GM-CSFstained cells converted into infectious titres ( Figure 2d ). The insert stability emerged to be very high with only a negligible decrease in VLPs harvested on day 4. Thus for this construct, genetic stability appeared to be very high.
KUN GM-CSF VLP treatment of CT26 tumours
To test the anti-cancer activity of intra-tumoral KUN GM-CSF VLP therapy, CT26 colon carcinoma cells were injected subcutaneously (s.c.) on the back of Balb/c mice. After 3 days, when the tumours had reached a mean size of B9 mm 2 (range: 6-12), they were treated daily for 10 days with intra-tumoral injections of KUN GM-CSF VLPs, KUN control VLPs, medium, or received no treatment. Tumour size was monitored and animals euthanized when the tumours reached 100 mm 2 . Animals treated with KUN GM-CSF VLPs survived significantly longer than animals receiving KUN control VLPs (log rank test: P ¼ 0.017). KUN control VLP-treated animals also survived longer than animals treated with medium, or animals receiving no treatment (log rank test P ¼ 0.019 for both) (Figure 3a ). The tumours in 50% of the animals treated with KUN GM-CSF VLPs grew to 20-50 mm 2 , but then started to regress around days 7-12 and became undetectable by day 18, and remained undetectable until the end of the experiment on day 64 ( Figure 3b , black squares, labelled 'cured'). The tumours in the remaining animals in the KUN GM-CSF VLP treatment group grew marginally slower than tumours in the other groups, but ultimately all reached 100 mm 2 ( Figure 3b , black squares, labelled 'not cured'). In six separate repeat experiments, KUN GM-CSF VLP treatment was able to (Table 1) , with survival and growth curves similar to those shown in Figure 3 (data not shown). At the 2 Â 10 6 IU dose, KUN control VLP treatment neither regressed nor cured any of the tumours (Table 1) .
CD8 T-cell induction by KUN GM-CSF VLP treatment of CT26 tumours
The dominant CD8 T-cell epitope presented by CT26 tumours is SPSYVYHQF, and regression of CT26 tumours by intra-tumoral DISC/HSV-GM-CSF treatment correlated with the induction of SPSYVYHQF-specific CD8 T-cell responses. 25 To determine whether regression of CT26 tumours also correlated with such responses, mice were treated as in Figure 3 except that on day 10 the mice were euthanized, and splenocytes were analyzed for SPSYVYHQF-specific T cells by ex vivo IFN-g ELI-SPOT. Mice with progressing tumours after treatment with medium, KUN control VLPs or KUN GM-CSF VLPs all exhibited similar CD8 T-cell responses (Figure 4a ). The tumours in these mice showed growth curves very similar to those shown in Figure 3b (data not shown). Mice with regressing tumours after treatment with KUN GM-CSF VLPs showed significantly higher SPSYVYHQF-specific responses (Mann-Whitney test, P ¼ 0.024). The tumours in these mice showed growth curves very similar to those shown in Figure 3b , cured (data not shown). Thus, regression of CT26 tumours after treatment with KUN GM-CSF VLPs also correlated with the induction of tumour-specific CD8 T cells.
Animals cured by KUN GM-CSF VLP treatment were resistant to CT26 challenge A group of animals cured of their CT26 tumours by KUN GM-CSF VLP treatment (Table 1) were rechallenged 35-42 weeks later with CT26 tumours. Compared with control animals the previously treated and cured animals were significantly more resistant to the challenge (log rank test, P ¼ 0.016) (Figure 4b ). This experiment provides further evidence that KUN GM-CSF VLP-mediated cure of CT26 tumours resulted in the induction of an adaptive immune response, which could be recalled after a significant period. A
KUN GM-CSF VLP treatment resulted in the regression of distant metastases
GM-CSF gene therapy of primary tumours has been shown earlier to result in the induction of anti-cancer CD8 T cells that not only regressed the treated tumours but also regressed distant metastases (which were not being directly treated with the gene therapy). 2, 25 To determine whether KUN GM-CSF VLP treatment of subcutaneous tumours would also lead to the regression of distant lung metastases, groups of mice were inoculated on the same day with CT26 tumours (i) by the subcutaneous route to establish the nominal primary tumours and (ii) by the intravenous route to establish lung metastases. When the primary tumours reached B10 mm 2 , they were treated with GM-CSF VLPs or medium as in Figure 3 . Mice whose primary tumours were treated with KUN GM-CSF VLPs (Figure 4c , KUN GM-CSF VLPs, i.t.) had significantly lower levels of lung metastases (Mann-Whitney test, P ¼ 0.027) than those whose primary tumours were treated with medium ( Figure 4c , medium i.t.). A further control group ( Figure  4c , no primary tumours), which received lung metastases but no primary tumours, developed more lung metastases than animals that received both lung metastases and primary tumours (Figure 4c , medium i.t). Thus, as observed earlier in this model, 25 a primary tumour seems to be capable of suppressing the growth of lung metastases. However, this suppression was clearly significantly (P ¼ 0.027) augmented when the primary tumours were treated with KUN GM-CSF VLPs. A similar result was reported for i.t. DISC/HSV-GM-CSF treatment. 25 This experiment again supports the contention that CD8 T-cell induction underpins the mechanism of action of KUN GM-CSF VLP treatment, and also illustrates an important advantage of this kind of therapy, namely regression of distant metastases.
Scheduling and dosing
A number of different treatment schedules were tested in the CT26 system (Table 2 ). Ten daily treatments (using an overall treatment dose of 20 Â 10 6 IU) of KUN GM-CSF VLPs appeared to be optimal, with reduced injection frequencies resulting in significant reductions in cure rates. Increasing the dose five fold (10 Â 10 7 ) with a schedule of 10 daily injections also provided no increase in cure rates (Table 2) . Interestingly, with this dose and schedule, KUN control VLPs yielded a 38% cure rate, illustrating that the anti-cancer activity of KUN control VLPs seen in Figures 3 and 5 is sufficient to cure these tumours when the dose of VLPs is sufficiently high.
KUN GM-CSF VLP treatment of B16-OVA tumours
To determine whether KUN GM-CSF VLP therapy might have utility in other tumour types and other mouse strains, B16-OVA melanoma tumours growing in C57BL/6 mice were treated as described in Figure 3 . A cure rate of 67% was achieved (log-rank test: Po0.001) following KUN GM-CSF VLP therapy (Figure 5a ). KUN control VLP treatment was again able to delay the growth significantly, but not cure any of the tumours (log-rank test: Po0.001) (Figure 5a ). Growth curves (plotted as in Figure 3b We have tested the KUN GM-CSF VLP therapy described in Figure 3 in a range of other tumour models (B16, AE17, TUBO, MC38 and 4T1) and in all cases the therapy was able to delay tumour growth significantly; however, tumour cure was rare or inconsistent ( Table 1) .
Expression of GM-CSF and IFN-a in vivo
To confirm that KUN GM-CSF VLP treatment actually results in GM-CSF production within the tumours in vivo, the experiment described in Figure 5a was repeated except that on day 5, tumours were excised and analyzed for GM-CSF mRNA using real-time PCR. KUN GM-CSF VLP-treated tumours contained B3.5-4 logs more GM-CSF mRNA than tumours treated with KUN control VLPs or medium (Figure 5c , GM-CSF), providing compelling evidence that KUN GM-CSF VLP treatment results in substantial replicon-derived GM-CSF expression in vivo.
Replicon dsRNA replication intermediates induced IFN-a/b production in vitro (Figure 2a) . To determine whether KUN VLP treatment also induced type I IFN expression in vivo, the tumours described above were also analyzed for the expression of IFN-a mRNA using real-time PCR. Both KUN GM-CSF VLP-and KUN control VLP-treated tumours contained 3.3-to 4.2-fold more IFN-a mRNA than tumours treated with medium ( Figure 5c, IFN-a) , illustrating that replicons delivered i.t. induced local production of type I IFNs.
Discussion
Here we illustrate the utility of the KUN replicon vector system in intra-tumoral cancer gene therapy and show that KUN VLPs encoding GM-CSF were able to cure a significant proportion of established tumours in at least two model systems, CT26 colon carcinomas grown in BALB/c mice and B16-OVA melanomas grown in C57BL/6 mice. Only a few immune-based strategies are able to cure established CT26 or B16-OVA tumours of reasonable size. 25, [52] [53] [54] Many strategies can prevent implantation of such tumours in wholly unrealistic prophylactic settings where vaccination precedes tumour challenge. However, such experiments are entirely distinct from therapy, where treatment is initiated after the tumour is established and actively growing. We propose that the efficiency of this treatment modality arises from the synergy between GM-CSF production and IFN-a/b induction for induction of anti-cancer CD8 T cells. 24, 36, 37 As with most intra-tumoral gene delivery systems, the level of transfection in vivo is likely to be an important factor. 4 We have tested the transfection efficiency of a number of tumour cell lines in vitro and found that at MOI ¼ 10, 1-5% of CT26 cells and 10-20% of B16-OVA cells are transfected, with Vero and BHK cell transfection usually reaching 50-90% (data not shown). This suggests that there may be room for improving the vector to maximize transfection efficiency. Passaging of KUN virus swarms on specific cancer lines should allow isolation of viruses with favourable mutations, which can then be introduced into KUN vectors to enhance their transfection efficiency for those lines. This approach has already illustrated that certain mutations in structural or non-structural genes can lead to large increases in transfection efficiency in specific cell lines. 38, 55 One of the problems associated with repeated use of viral vectors is that antibodies specific for the vector are eventually generated that can compromise subsequent treatment rounds. We have observed that neutralizing antibody responses are generated in the mice after 10 daily i.t. injections (data not shown) and these may interfere with subsequent rounds of VLP treatment. KUN replicons can also be delivered as DNA or RNA and such modalities are unlikely to be affected by neutralizing antibodies. However, intra-tumoral RNAbased delivery (10 mg RNA per day for 10 days) of KUN GM-CSF (even with protamine to stabilize the RNA 56 ) failed to generate significant anti-cancer activity (data not shown). Intra-tumoral DNA-based delivery of KUN replicons encoding GM-CSF remains to be tested; however, strategies such as gene gun delivery 57 or in vivo electroporation 58 are likely needed to increase the transfection efficiency. In summary, this study illustrates the utility of the KUN replicon GM-CSF VLP system for tumour gene therapy. The KUN replicon may also find utility for delivering other therapeutic genes which are likely to synergize with dsRNA-induced 'danger signals' to generate anti-cancer activity; inter alia tumour necrosis factor family members, 53, 59 IL-3, 60 or IL-24.
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Materials and methods
Production of KUN VLPs pKUNrep4 has been described earlier. 12 pKUNrep5 was prepared by deleting the puromycin N-acetyltransferase gene from pKUNrep4. Sp6KUNrep5 is a derivative of pKUNrep5 and was prepared by replacing the cytomegalovirus promoter with an SP6 promoter. The murine GM-CSF sequence was PCR amplified with Pfu DNA polymerase (Promega, Sydney, Australia) from the plasmid pEF-BOS/GM-CSF (a kind gift from Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA), using forward (5 0 -GCGGACGCGTATGCCC ACGAGAGAAAGGCTAAG-3 0 ) and reverse (5 0 -GCG ACGCGTCATTTTTGGACTGGTTTTTTGC-3 0 ) primers with incorporated MluÉ restriction sites (underlined). The GM-CSF gene was then cloned into the MluI site in between the FMDV2A site and the encephalomyocarditis virus IRES of Sp6KUNrep5. The control KUN constructs encoding b-galactosidase or nothing have been described earlier. 62, 63 For VLP generation, Kunjin replicon RNAs were transcribed in vitro using SP6 RNA polymerase and electroporated into tetKUNCprME BHK packaging cells essentially as described earlier.
8 RNA (20-30 mg) was electroporated into 3 Â 10 6 packaging cells in suspension and the cells were seeded into a 100 mm dish and incubated at 37 1C for 2-4 days. Culture fluid was collected at days 2-4 and the VLPs purified by first concentrating the cleared supernatants by tangential flow filtration (300 kDa cutoff) (LabScale TFF System; Millipore, Sydney, North Ryde, Australia) and then spinning the preparation through a sucrose cushion (12.5% sucrose and 2.5% trehalose). The pellets were then resuspended in DMEM (Dulbecco's modified Eagle's medium) and frozen at À70 1C in aliquots. The aliquots were thawed before use and stored at 4 1C for up to 3 days for later use.
The titre of infectious VLPs was determined by infection of Vero cells with 10-fold serial dilutions of the culture fluid. At 30-40 h post-infection, the cells were fixed with methanol/acetone (1:1 v/v) and analyzed by IFA staining using 4G4 monoclonal anti-NS1 64, 65 and an anti-murine GM-CSF antibody (BD Biosciences, Sydney, North Ryde, NSW, Australia), and Oregon green 488-conjugated goat anti-mouse or AlexaFlour 549-conjugated goat anti-rat antibodies, respectively (both from Molecular Probes, Eugene, OR, USA) used as secondary antibodies. The number of positive cells on the entire Normalized GM-CSF mRNA expression ± s.e. ) in six well plates were infected by KUN replicon VLPs encoding either WT NS2A or A30P mutated NS2A at MOI ¼ 1. Cell culture fluid (2 ml) was collected at 18 h post-infection. Secreted IFN-a/b was determined by IFN-a/b bioassay in duplicate 67 using IFN-a2 (Roche, Basel, Switzerland) as a standard.
Tumour models and treatment
BALB/c mice (4-to 6-week-old) were injected day À3 s.c. on the shaved back with CT26 cells 25 (2-3 Â 10 5 cells in 50 ml of RPMI1640). C57BL/6 mice were similarly injected with 10 6 B16-OVA melanoma cells. 63 On day 0, animals were sorted into groups so that each group had approximately the same range of tumour sizes and the same mean tumour area. Unless otherwise stated, tumours were injected i.t. with a 27 gauge needle daily for 10 days with VLPs (2 Â 10 6 IU in 40 ml DMEM), medium (40 ml DMEM) or were left untreated. The mice were restrained in a special holder that allowed easy access to the tumour and the needle was passed through the tumour and slowly withdrawn with each daily injection following a different path. In rechallenge experiments mice received 10 5 CT26 cells s.c. in 100 ml of RPMI1640. To establish lung metastases, CT26 cells (5 Â 10 4 in 100 ml RPMI1640) were inoculated intravenously on day À3. All animal experiments were approved by the QIMR animal ethics committee and treatments were approved by the Australian Office of the Gene Technology Regulator (DNIR 292/204).
ELISPOT assay
Mouse splenocytes were analyzed by ex vivo IFN-g ELISPOT as described, 68 but using MultiScreen-IP plates (Millipore), 10 IU ml À1 of recombinant human IL-2 (Cetus Corp., Emeryville, CA, USA) and 2 mg ml À1 of the SPSYVYHQF peptide, the dominant AH1 epitope from CT26 tumours. 25 
Real-time PCR
Subcutaneous B16-OVA tumours were treated as described above for 4 days and excised on day 5, placed into RNAlater Solution (Ambion, Austin, TX, USA), cut into small pieces and left for 24 h at 4 1C. RNA was extracted using TRIzol Reagent (Invitrogen, Thornton, NSW, Australia) according to the manufacturer's instructions. First-strand total cDNA synthesis was performed in a 20 ml reaction containing 1 mg of total RNA, 500 mM dNTPs, 200 ng of random hexamer oligonucleotides, 1 Â Superscript first-strand buffer, 10 70 5 0 -GAGGTCGGGTG GAAGTACCA-3 0 and 5 0 -TGCATCTTGGCCTTTTCCTT-3 0 . The amplification reaction mixture of 20 ml contained 2 ml of randomly primed cDNA, 0.5 mM each primer pair and 10 ml of 2 Â Platinum SYBR Green qPCR Supermix-UDG (Invitrogen). Cycling conditions were as follows: one cycle of 50 1C for 2 min and one cycle of 95 1C followed by 45 cycles of 94 1C for 5 s, 60 1C for 10 s and 72 1C for 40 s. The real-time PCR was performed using a Rotorgene PCR machine (Corbett Research, Mortlake, NSW, Australia). PCR products were visualized with SYBR green dye and analyzed with Rotorgene Real-Time Analysis software (Corbett Research). Samples were analyzed in duplicate, and GM-CSF and IFN-a mRNA levels were normalized to RPL13A mRNA for each sample. 70 
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